LMDX.F Stock Overview
LumiraDx Limited operates as a point of care diagnostics company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
LumiraDx Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.016 |
| 52 Week High | US$0.61 |
| 52 Week Low | US$0.007 |
| Beta | 1.45 |
| 1 Month Change | 113.33% |
| 3 Month Change | 15.11% |
| 1 Year Change | -96.94% |
| 3 Year Change | -99.84% |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower
Dec 20
LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors
Apr 17What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today
Nov 16Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022
Aug 20LumiraDx GAAP EPS of -$0.58, revenue of $44.7M
Aug 18Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx
Jul 15Shareholder Returns
| LMDX.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.9% | -0.9% | -0.7% |
| 1Y | -96.9% | -2.0% | 22.3% |
Return vs Industry: LMDX.F underperformed the US Medical Equipment industry which returned -2% over the past year.
Return vs Market: LMDX.F underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| LMDX.F volatility | |
|---|---|
| LMDX.F Average Weekly Movement | 28.3% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LMDX.F's share price has been volatile over the past 3 months.
Volatility Over Time: LMDX.F's weekly volatility has decreased from 39% to 28% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,210 | Veronique Ameye | www.lumiradx.com |
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx Limited Fundamentals Summary
| LMDX.F fundamental statistics | |
|---|---|
| Market cap | US$8.25m |
| Earnings (TTM) | -US$338.03m |
| Revenue (TTM) | US$126.52m |
0.0x
P/S Ratio0.0x
P/E RatioIs LMDX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMDX.F income statement (TTM) | |
|---|---|
| Revenue | US$126.52m |
| Cost of Revenue | US$131.23m |
| Gross Profit | -US$4.71m |
| Other Expenses | US$333.32m |
| Earnings | -US$338.03m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -3.73% |
| Net Profit Margin | -267.19% |
| Debt/Equity Ratio | -201.0% |
How did LMDX.F perform over the long term?
See historical performance and comparison